Legal & General Group Plc Increases Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legal & General Group Plc lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 151,550 shares of the medical equipment provider’s stock after acquiring an additional 3,117 shares during the period. Legal & General Group Plc’s holdings in Lantheus were worth $13,558,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. HighTower Advisors LLC bought a new stake in shares of Lantheus in the 3rd quarter valued at approximately $607,000. MML Investors Services LLC lifted its position in Lantheus by 24.6% in the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider’s stock worth $476,000 after buying an additional 857 shares during the last quarter. M&T Bank Corp lifted its position in Lantheus by 40.4% in the third quarter. M&T Bank Corp now owns 6,847 shares of the medical equipment provider’s stock worth $752,000 after buying an additional 1,969 shares during the last quarter. Coldstream Capital Management Inc. bought a new position in Lantheus during the third quarter valued at $230,000. Finally, World Investment Advisors LLC purchased a new stake in shares of Lantheus in the third quarter valued at $60,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock valued at $6,016,046 over the last three months. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $102.78 on Wednesday. Lantheus Holdings, Inc. has a 52-week low of $59.56 and a 52-week high of $126.89. The firm has a market capitalization of $7.04 billion, a price-to-earnings ratio of 17.10 and a beta of 0.20. The stock has a 50 day moving average price of $94.48 and a 200 day moving average price of $95.58.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LNTH shares. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Finally, B. Riley dropped their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.